ELYM ELIEM THERAPEUTICS INC

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Guggenheim’s 4th Annual Immunology and Neurology Conference

Fireside Chat Date: November 15, 2022

Fireside Chat Time: 10:10 a.m. ET

Location: St. Regis Hotel, New York, NY

Stifel 2022 Healthcare Conference

Fireside Chat date: Wednesday, November 16, 2022

Fireside Chat time: 1:50 p.m. ET

Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the fireside chat presentations will be available on the Investors section of the Eliem Therapeutics website at . An archived replay of each of the events will remain available on Eliem’s website for at least 30 days after the event.

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

Investors

Chris Brinzey

ICR Westwicke



339-970-2843

Media

Marites Coulter

Verge Scientific



415.819.2214



EN
08/11/2022

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4...

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio’s 2025 Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was grant...

November 25, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Bu...

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate CLYM116 Phase 1 trial; anticipate dosing first subject by year-end, with initial data expected mid-2026 Leaders...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Guggenheim's 2nd Annual Healthcare Innovation ConferenceLocation: BostonFormat: Fireside chat and one-on-one investor meetingsDate: Monday, November 10, 2025Time: 11:30 a.m. ET Baird Biotech Discovery SeriesLocation: VirtualFormat: Fir...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jon...

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy. “We are thrilled to welcome Adam and Ashley to the Climb Bio leadership team,” said A...

October 21, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidn...

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for budoprutug, anti-CD19 monoclonal antibody, support potential for therapeutic benefit in primary membranous nephropathy (pMN) WELLESLEY HILLS, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients wit...

October 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch